$264 Million is the total value of Decheng Capital Management III (Cayman), LLC's 25 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ZNTL | New | Zentalis Pharmaceuticals Inc. | $51,271,000 | – | 1,824,583 | +100.0% | 19.44% | – |
| HZNP | New | Horizon Therapeutics PLC | $4,419,000 | – | 55,400 | +100.0% | 1.68% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-01
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Illumnia, Inc. | 7 | Q3 2023 | 16.5% |
| Cue Health Inc. | 7 | Q3 2023 | 17.8% |
| Arcus BioSciences, Inc. | 7 | Q3 2023 | 8.4% |
| 10x Genomics, Inc. | 7 | Q3 2023 | 8.1% |
| Pacific Biosciences of California, Inc. | 7 | Q3 2023 | 6.8% |
| Equillium Inc. | 7 | Q3 2023 | 4.3% |
| Aadi Bioscience, Inc. | 7 | Q3 2023 | 2.7% |
| Adicet Bio, Inc. | 7 | Q3 2023 | 3.6% |
| Aura Biosciences, Inc. | 7 | Q3 2023 | 6.1% |
| Terns Pharmaceuticals, Inc. | 7 | Q3 2023 | 3.4% |
View Decheng Capital Management III (Cayman), LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-01-22 |
| 13F-HR/A | 2023-12-12 |
| 13F-HR/A | 2023-11-29 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-07-28 |
| 13F-HR | 2023-05-10 |
| 13F-HR | 2023-02-09 |
| 13F-HR | 2022-11-08 |
| 4 | 2022-09-27 |
| 13F-HR | 2022-08-01 |
View Decheng Capital Management III (Cayman), LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.